Possible malignant neuroleptic syndrome that associated with hypothyroidism

Basit Öğe Kaydı
dc.authoridtaskapan, hulya/0000-0001-8736-4779
dc.authoridTaskapan, Mehmet Cagatay/0000-0002-5273-4909
dc.authorwosidtaskapan, hulya/ABI-7737-2020
dc.authorwosidTaskapan, Mehmet Cagatay/ABI-7747-2020
dc.contributor.authorTaskapan, C
dc.contributor.authorSahin, I
dc.contributor.authorTaskapan, H
dc.contributor.authorKaya, B
dc.contributor.authorKosar, F
dc.date.accessioned2024-08-04T20:14:48Z
dc.date.available2024-08-04T20:14:48Z
dc.date.issued2005
dc.departmentİnönü Üniversitesien_US
dc.description.abstractA 54-year-old woman with schizophrenia presented to hospital with unconsciousness, fever and marked muscle rigidity. She had been given fluphenazine decanoete 20 mg intramuscularly 15 days before the admission and she had continued taking haloperidol 20 mg daily and oral biperiden 2-4 mg. She was extremely rigid and unresponsive. On laboratory investigations revealed: serum sodium 120 mEq/l, creatinine phosphokinase 12,980 IU/l (normal up to 170), lactate dehydrogenase 1544 IU/l (150-500), free trioidothyronine <1.00 pg/ml (1.5-4.5), free throxyine 0.76 ng/dl (0.8-1.9), thyroid stimulating hormone 1.14 mu U/ml (0.4-4), cortisol (at 8.00 a.m.) 9 mu g/dl (5-25). Antipsychotic drugs were withdrawn after admission. A diagnosis of secondary adrenal insufficiency and secondary hypothyroidism was made. Hormonal substitution with hydrocortisone and levothyroxine and correction of hyponatremia with intravenous hypertonic saline solution resulted in rapid improvement of symptoms and signs. It seems that the symptoms and signs of hypothyroidism and hyponatremia were attributed to acute psychosis in this patient. As a conclusion failure to recognize the endocrinopathy may not only produce recovery difficulties but also psychiatric and endocrine repercussions if psychotropic medications are given in such masked cases. (C) 2005 Elsevier Inc. All rights reserved.en_US
dc.identifier.doi10.1016/j.pnpbp.2005.04.004
dc.identifier.endpage748en_US
dc.identifier.issn0278-5846
dc.identifier.issn1878-4216
dc.identifier.issue5en_US
dc.identifier.pmid15927337en_US
dc.identifier.scopus2-s2.0-21244455731en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage745en_US
dc.identifier.urihttps://doi.org/10.1016/j.pnpbp.2005.04.004
dc.identifier.urihttps://hdl.handle.net/11616/93978
dc.identifier.volume29en_US
dc.identifier.wosWOS:000230586100016en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.ispartofProgress in Neuro-Psychopharmacology & Biological Psychiatryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjecthyponatremiaen_US
dc.subjecthypothyroidismen_US
dc.subjectmalignant neuroleptic syndromeen_US
dc.subjectneurolepticsen_US
dc.subjectrhabdomyolysisen_US
dc.titlePossible malignant neuroleptic syndrome that associated with hypothyroidismen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu